Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CASP3 | P42574 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.31 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.31 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30357025 | 1.00 | ESR2 (0.42) | ESR2HRH3BACE1NPC1CASP3 | |
| SCHEMBL9019416 | 0.85 | ESR2 (0.43) | ESR2HRH3BACE1NPC1CASP3 | |
| SCHEMBL31279683 | 0.83 | ESR2 (0.41) | ESR2HRH3BACE1NPC1CASP3 | |
| SCHEMBL15255856 | 0.83 | ESR2 (0.41) | ESR2HRH3BACE1NPC1CASP3 | |
| SCHEMBL22122631 | 0.83 | ESR2 (0.41) | ESR2HRH3BACE1NPC1CASP3 | |
| SCHEMBL10015003 | 0.82 | ESR2 (0.40) | ESR2HRH3BACE1NPC1CASP3 | |
| SCHEMBL9828942 | 0.82 | ESR2 (0.40) | ESR2HRH3BACE1NPC1CASP3 | |
| SCHEMBL20797236 | 0.81 | ESR2 (0.48) | ESR2BACE1NPC1CASP3RAB9A | |
| SCHEMBL11190434 | 0.81 | ESR2 (0.54) | ESR2BACE1NPC1CASP3RAB9A | |
| SCHEMBL10931526 | 0.80 | ESR2 (0.47) | ESR2BACE1NPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3874009-B1 | DIBENZOFURAN AND DIBENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2024-08-21 | — | — | EP | disclosed |
| EP-4189035-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS | Merck Patent GmbH (DE) | 2023-06-07 | — | — | EP | disclosed |
| US-11667841-B2 | Dibenzofuran and dibenzothiophene derivatives | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11667841-B2 | Dibenzofuran and dibenzothiophene derivatives | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| US-11667841-B2 | Dibenzofuran and dibenzothiophene derivatives | MERCK PATENT GMBH (DE) | 2023-06-06 | — | — | US | disclosed |
| US-20230061307-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS | MERCK PATENT GMBH (DE) | 2023-03-02 | — | — | US | disclosed |
| WO-2022023400-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS | MERCK PATENT GMBH (DE) | 2022-02-03 | — | — | WO | disclosed |
| US-20210403810-A1 | DIBENZOFURAN AND DIBENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-12-30 | — | — | US | disclosed |
| US-20210403810-A1 | DIBENZOFURAN AND DIBENZOTHIOPHENE DERIVATIVES | MERCK PATENT GMBH (DE) | 2021-12-30 | — | — | US | disclosed |
| EP-3898891-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS | Merck Patent GmbH (DE) | 2021-10-27 | — | — | EP | disclosed |
| CN-113508168-A | Compound, liquid crystal medium and liquid crystal display comprising same | 默克专利股份有限公司 | 2021-10-15 | — | — | CN | disclosed |
| EP-3874009-A1 | DIBENZOFURAN AND DIBENZOTHIOPHENE DERIVATIVES | Merck Patent GmbH (DE) | 2021-09-08 | — | — | EP | disclosed |
| WO-2020127172-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | WO | disclosed |
| WO-2020127172-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS | MERCK PATENT GMBH (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-8187494-B2 | Four- or five-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100309402-A1 | FOUR- OR FIVE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | KIF23, HCN3, FZD7 | ESR2 2689/4885HRH3 356/4885BACE1 3312/4885 |
| US-11667841-B2 | Dibenzofuran and dibenzothiophene derivatives | DDT, MYT1, DBF4 | ESR2 3924/4885HRH3 3986/4885BACE1 1547/4885 |
| US-20210403810-A1 | DIBENZOFURAN AND DIBENZOTHIOPHENE DERIVATIVES | DDT, MYT1, DBF4 | ESR2 3924/4885HRH3 3986/4885BACE1 1547/4885 |
| US-20230061307-A1 | LIQUID-CRYSTALLINE MEDIUM AND LIQUID-CRYSTAL DISPLAY COMPRISING THE SAME AND COMPOUNDS | NEFM, FES, EML4 | ESR2 2610/4885HRH3 3732/4885BACE1 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.